{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:25Z","timestamp":1784119585329,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970815"],"award-info":[{"award-number":["81970815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00417-023-06224-9","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:02:15Z","timestamp":1696932135000},"page":"1409-1419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials"],"prefix":"10.1007","volume":"262","author":[{"given":"Miao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"6224_CR1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O (2013) Retinopathy of prematurity. Lancet 382:1445\u20131457","journal-title":"Lancet"},{"key":"6224_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol (Chicago, Ill.\u202f: 1960) 121:1684\u201394","journal-title":"Arch Ophthalmol (Chicago, Ill. : 1960)"},{"key":"6224_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archophthalmol.2010.360","volume":"129","author":"GE Quinn","year":"2011","unstructured":"Quinn GE, Dobson V, Hardy RJ, Tung B, Palmer EA, Good WV (2011) Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity. Arch Ophthalmol 129:127\u2013132","journal-title":"Arch Ophthalmol"},{"key":"6224_CR4","first-page":"225","volume":"103","author":"BT Smith","year":"2005","unstructured":"Smith BT, Tasman WS (2005) Retinopathy of prematurity: late complications in the baby boomer generation (1946\u20131964). Trans Am Ophthalmol Soc 103:225\u201334 (discussion 34-6)","journal-title":"Trans Am Ophthalmol Soc"},{"key":"6224_CR5","doi-asserted-by":"crossref","unstructured":"Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, Yap VL, Chiang MF, Chan RVP, Wu WC (2021) Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res 88:101018","DOI":"10.1016\/j.preteyeres.2021.101018"},{"key":"6224_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","volume":"124","author":"DK VanderVeen","year":"2017","unstructured":"VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR (2017) Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology 124:619\u2013633","journal-title":"Ophthalmology"},{"key":"6224_CR7","first-page":"Cd009734","volume":"1","author":"MJ Sankar","year":"2018","unstructured":"Sankar MJ, Sankar J, Chandra P (2018) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 1:Cd009734","journal-title":"Cochrane Database Syst Rev"},{"key":"6224_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844","journal-title":"Nature"},{"key":"6224_CR9","first-page":"1162","volume":"368","author":"ME Hartnett","year":"2013","unstructured":"Hartnett ME, Penn JS (2013) Mechanisms and management of retinopathy of prematurity. N Engl J Med 368:1162\u20131163","journal-title":"N Engl J Med"},{"key":"6224_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","volume":"22","author":"R Autrata","year":"2012","unstructured":"Autrata R, Krej\u010d\u00ed\u0159ov\u00e1 I, \u0160enkov\u00e1 K, Holou\u0161ov\u00e1 M, Dole\u017eel Z, Borek I (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22:687\u2013694","journal-title":"Eur J Ophthalmol"},{"key":"6224_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"6224_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet (London, England) 394:1551\u20131559","journal-title":"Lancet (London, England)"},{"key":"6224_CR13","doi-asserted-by":"crossref","unstructured":"Wu Z, Zhao J, Lam W, Yang M, Chen L, Huang X, Wei M, Yang H, Lv F, Zhang F, Zeng J, Zhang GM (2021) Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol 106:975\u2013979","DOI":"10.1136\/bjophthalmol-2020-318026"},{"key":"6224_CR14","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, Dastjani Farahani A, Ebrahimi Adib N, Torabi H (2016) Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 94:e417\u2013e420","journal-title":"Acta Ophthalmol"},{"key":"6224_CR15","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"6224_CR16","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"6224_CR17","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8:e76654","journal-title":"PLoS One"},{"key":"6224_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"6224_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110","journal-title":"Res Synth Methods"},{"key":"6224_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:932\u2013944","journal-title":"Stat Med"},{"key":"6224_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163\u2013171","journal-title":"J Clin Epidemiol"},{"key":"6224_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, Li H, Tian R, Li N, Tang S, He H, Tan W, Song X, Zhuang R (2017) Comparison Of Intravitreal Injection Of Ranibizumab Versus Laser Therapy For Zone Ii Treatment-Requiring Retinopathy Of Prematurity. Retina 37:710\u2013717","journal-title":"Retina"},{"key":"6224_CR23","first-page":"595","volume":"36","author":"H Zhang","year":"2020","unstructured":"Zhang H, Yang X, Wan S, Xu Y (2020) Comparison of the effect of intravitreal injection of conbercept with different doses in the treatment of retinopathy of prematurity. Chin J Ocul Fundus Dis 36:595\u2013599","journal-title":"Chin J Ocul Fundus Dis"},{"key":"6224_CR24","first-page":"356","volume":"38","author":"G Wang","year":"2017","unstructured":"Wang G, Gao X (2017) Effect of ranibizumab on the VEGF, IGF-1 and GLU levels in premature with retinopathy. Med J NDFNC 38:356\u2013360 (in Chinese)","journal-title":"Med J NDFNC"},{"key":"6224_CR25","first-page":"109","volume":"42","author":"S Sun","year":"2020","unstructured":"Sun S, Sun X, Lu Y (2020) The efficacy among different dose of intravitreal conbercept injection for the treatment of retinopathy of prematurity. Chin J Ocul Traum Occupat Eye Dis 42:109\u2013112 (in Chinese)","journal-title":"Chin J Ocul Traum Occupat Eye Dis"},{"key":"6224_CR26","unstructured":"Tong L, Lin C, Lin L, Lv Y, Xiong Y (2021) Effect of laser photocoagulation combined with intravitreal injection of ranibizumab on retinopathy of premature. China Prac Med 16:111\u2013113 (in Chinese)"},{"key":"6224_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Lois S, Walz J (2018) Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: a Randomized Clinical Trial. JAMA Pediatr 172:278\u2013286","journal-title":"JAMA Pediatr"},{"key":"6224_CR28","doi-asserted-by":"crossref","unstructured":"Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M (2018) Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. J Curr Pphthalmol 31:61\u201365","DOI":"10.1016\/j.joco.2018.10.008"},{"key":"6224_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl A, Sukgen EA, Wu W-C, Lepore D, Nakanishi H, Mazela J, Moshfeghi DM, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Schmelter T, Leal S, Kofuncu E, Azuma N, Grp FS (2022) Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity The FIREFLEYE Randomized Clinical Trial. Jama-J Am Med Assoc 328:348\u2013359","journal-title":"Jama-J Am Med Assoc"},{"key":"6224_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","volume":"38","author":"E Jin","year":"2018","unstructured":"Jin E, Yin H, Li X, Zhao M (2018) Short-Term Outcomes After Intravitreal Injections Of Conbercept Versus Ranibizumab For The Treatment Of Retinopathy Of Prematurity. Retina 38:1595\u20131604","journal-title":"Retina"},{"key":"6224_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","volume":"26","author":"M Zhang","year":"2009","unstructured":"Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26:204\u2013210","journal-title":"Pharm Res"},{"key":"6224_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","volume":"97","author":"H Li","year":"2012","unstructured":"Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X (2012) Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 97:154\u2013159","journal-title":"Exp Eye Res"},{"key":"6224_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA (2018) Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J aapos 22:61-65.e1","journal-title":"J aapos"},{"key":"6224_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","volume":"128","author":"CY Tsai","year":"2021","unstructured":"Tsai CY, Yeh PT, Tsao PN, Chung YE, Chang YS, Lai TT (2021) Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis. Ophthalmology 128:877\u2013888","journal-title":"Ophthalmology"},{"key":"6224_CR35","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","volume":"125","author":"DK Wallace","year":"2018","unstructured":"Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT (2018) A Dosing Study of Bevacizumab for Retinopathy of Prematurity: late Recurrences and Additional Treatments. Ophthalmology 125:1961\u20131966","journal-title":"Ophthalmology"},{"key":"6224_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","volume":"138","author":"DK Wallace","year":"2020","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski M, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong LK, Cotter SA, Holmes JM (2020) Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol 138:698\u2013701","journal-title":"JAMA Ophthalmol"},{"key":"6224_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","volume":"138","author":"ER Crouch","year":"2020","unstructured":"Crouch ER, Kraker RT, Wallace DK, Holmes JM, Repka MX, Collinge JE, Bremer DL, Gray ME, Smith HA, Steinkuller PG (2020) Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol 138:14\u201320","journal-title":"JAMA Ophthalmol"},{"key":"6224_CR38","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD (2017) Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina 37:1847\u20131858","journal-title":"Retina"},{"key":"6224_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","volume":"42","author":"M Gunay","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y (2017) Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Curr Eye Res 42:462\u2013469","journal-title":"Curr Eye Res"},{"key":"6224_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95\u2013113","journal-title":"Surv Ophthalmol"},{"key":"6224_CR41","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, Smith OE, Steinkuller PG (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6224_CR42","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, Mehler K, Oberthur A, Kirchhof B, Fauser S (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91:e74\u2013e75","journal-title":"Acta Ophthalmol"},{"key":"6224_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35:675\u2013680","journal-title":"Retina"},{"key":"6224_CR44","doi-asserted-by":"crossref","unstructured":"Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A, Li J, Weisberger A, Fielder AR, Group RI (2022) Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the rainbow trial. Ophthalmol Retina 6:628\u2013637","DOI":"10.1016\/j.oret.2022.02.006"},{"key":"6224_CR45","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.14852","volume":"100","author":"A Stahl","year":"2022","unstructured":"Stahl A, Br\u00fcnder MC, Lagr\u00e8ze WA, Moln\u00e1r FE, Barth T, Eter N, Guthoff R, Krohne TU, Pfeil JM (2022) Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Acta Ophthalmol 100:e91\u2013e99","journal-title":"Acta Ophthalmol"},{"key":"6224_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","volume":"5","author":"N Marlow","year":"2021","unstructured":"Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, Weisberger A, Stiehl DP, Fleck B (2021) 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health 5:698\u2013707","journal-title":"Lancet Child Adolesc Health"},{"key":"6224_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","volume":"18","author":"Z Li","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y (2018) Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol 18:19","journal-title":"BMC Ophthalmol"},{"key":"6224_CR48","doi-asserted-by":"publisher","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","volume":"13","author":"SD Wang","year":"2020","unstructured":"Wang SD, Zhang GM, Shenzhen Screening for Retinopathy of Prematurity Cooperative G (2020) Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int J Ophthalmol 13:806\u2013815","journal-title":"Int J Ophthalmol"},{"key":"6224_CR49","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","volume":"129","author":"E Chang","year":"2022","unstructured":"Chang E, Josan AS, Purohit R, Patel CK, Xue K (2022) A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Ophthalmology 129:1389\u20131401","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06224-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T11:09:49Z","timestamp":1713524989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06224-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6224"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06224-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}